Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)

NCT02489305 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to identify if there are self-reported or objective measures related to mood parameters that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for relapse) or early symptomatic changes indicative of relapse prodrome in major depressive disorder (MDD).

Conditions Studied

Study Locations (20)

California

  • — Glendale
  • — Oceanside
  • — San Diego
  • — Sherman Oaks
  • — Stanford

Florida

  • — Jacksonville
  • — Orlando
  • — Tampa

Illinois

  • — Chicago
  • — Skokie
  • — Springfield

Alabama

  • — Birmingham

Connecticut

  • — Hartford

Georgia

  • — Augusta

Iowa

  • — Iowa City

Kansas

  • — Wichita

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2014-12-15
Est. Completion 2018-05-01

Sponsor

Janssen Research & Development

442 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02489305

The ClinicalTrials.gov registry entry for NCT02489305 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 442 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02489305 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02489305 about?

NCT02489305 is a clinical study titled "Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)". The purpose of this study is to identify if there are self-reported or objective measures related to mood parameters that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for relapse) or early symptomatic changes indicative of relapse prod...

What is the current status of trial NCT02489305?

This trial is currently completed. The enrollment target is 330 participants. The study started on 2014-12-15. Estimated completion is 2018-05-01.

What conditions does trial NCT02489305 study?

This clinical trial studies the following conditions: Depressive Disorder, Major. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT02489305?

This trial is sponsored by Janssen Research & Development, which has 442 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02489305 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial